Quo vadis radioimmune and radiopeptide therapy?;Quo vadis radioimmun- und radiopeptidtherapie? Welche rolle spielen sie künftig im klinischen alltag?

NuklearMedizin

Volumn 41, Issue 6, 2002, Pages 230-232

  Behr, T M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE;

EDITORIAL; RADIOIMMUNOTHERAPY; RADIOTHERAPY;

EID: 0036924098     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625293     Document Type: Editorial

References (12)

1. Behr TM, Béhé M, Becker W. Radioimmuntherapie hämatologischer und solider Neoplasien. In: Kneba M, Dreger P, Pantel K (Hsg). Antikörpertherapie in der Hämatologie und Onkologie. Bremen, London, Boston: UNI-MED Science 2001, 157-75.
2. Behr TM, Béhé M, Kluge G et al. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: Facts and myths about the Scylla and Charybdis. Eur J Nucl Med 2002; 29: 277-9.
3. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: A review "Of Mice and Men". Hybridoma 1997; 16: 101-7.
4. Behr TM, Gotthardt M, Barth A et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45: 189-200.
5. Behr TM. Do we need myeloablative, high-dose therapy in radioimmunotherapy of non-Hodgkin's lymphoma? Eur J Nucl Med 2002; in press.
6. Bell E, Grünwald F. Radiojodtherapie bei Benignen und Malignen Schilddrüsenerkrankungen. Berlin, Heidelberg, New York: Springer 1999.
7. DeVita Jr. VT, Hellman S, Rosenberg SA (eds). Cancer - Principles and Practice of Oncology. Philadelphia, New York: Lippincott-Raven 1997, 5th ed.
8. Feld M, DeRoo M. Geschichte der Nuklearmedizin in Europa. Stuttgart, New York: Schattauer 2000.
9. Goldenberg DM, DeLand F, Kim E et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-6.
10. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713.
11. Gopal AK, Rajendran JG, Petersdorf SH et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-62.
12. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001; 12: 941-5.